参银口服液治疗轻度认知功能损害的临床研究

目的观察参银口服液治疗轻度认知功能损害（MCI）的疗效及降低阿尔茨海默病（AD）转化率的可能。方法117例MCI患者随机分为中药组（42例）、维生素E组（38例）和安慰剂组（37例）,疗程共12个月,随访至停药6个月。结果与治疗前比,治疗后中药组MCI患者画钟测验、无意义图形再认及简易精神状态量表（MMSE）分值均提高,均有统计学意义（P〈0.05或P〈0.01）。治疗后中药组红细胞膜乙酰胆碱酯酶活性低于安慰剂组及维生素E组（P〈0.05或P〈0.01）。停药6个月后安慰剂和维生素E组分别有2例和5例转化为AD,中药组未见转化病例。结论参银口服液具有类胆碱酯酶抑制剂作用,能改善MCI患者认知功能,对降低AD转化率有作用。

Clinical Study on Effect of Shenyin Oral Liquid in Treating Mild Cognitive Impairment

Objective To observe the therapeutic effect of Shenyin Oral Liquid (SOL) in relieving mild cognitive impairment (MCI) and decreasing the Alzheimer's disease (AD) transformation rate. Methods One hundred and seventeen MCI patients were randomly assigned to the Chinese medicine group (42 cases), the vitamin E group (38 cases) and the placebo group (37 cases). The treatment course was 12 months and a 6-month follow-up was conducted after ending the treatment course. Results After treatment, the scores of clock drawing test (CDT), nonsensical figure recognition and mini-mental state examination (MMSE) raised significantly in the Chinese medicine group (P<0.05 or P<0.01), the activity of acetylcholine esterase in erythrocytic membrane was lower in the Chinese medicine group than that in the placebo group and the Vitamin E group (P<0.05 or P<0.01). Six months after the treatment, there were 2 and 5 cases in the placebo group and the vitamin E group which were diagnosed as AD, respectively, and none in the Chinese medicine group. Conclusion SOL has an effect similar to cholinesterase inhibitor, it could improve cognitive function in MCI patients and reduce the AD transformation rate in them.